Published in J Clin Microbiol on August 01, 2003
In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One (2010) 4.08
High analytical sensitivity and low rates of inhibition may contribute to detection of Chlamydia trachomatis in significantly more women by the APTIMA Combo 2 assay. J Clin Microbiol (2006) 1.97
Home screening for sexually transmitted diseases in high-risk young women: randomised controlled trial. Sex Transm Infect (2007) 1.70
Incidence and risk factors for urethral and anal gonorrhoea and chlamydia in a cohort of HIV-negative homosexual men: the Health in Men Study. Sex Transm Infect (2006) 1.59
Characteristics of the m2000 automated sample preparation and multiplex real-time PCR system for detection of Chlamydia trachomatis and Neisseria gonorrhoeae. J Clin Microbiol (2007) 1.33
Vulvovaginal-swab or first-catch urine specimen to detect Chlamydia trachomatis in women in a community setting? J Clin Microbiol (2006) 1.14
Decline in the prevalence of HIV and sexually transmitted infections among female sex workers in Benin over 15 years of targeted interventions. J Acquir Immune Defic Syndr (2013) 0.94
Home versus clinic-based specimen collection for Chlamydia trachomatis and Neisseria gonorrhoeae. Expert Rev Anti Infect Ther (2011) 0.91
Linear nicking endonuclease-mediated strand-displacement DNA amplification. Anal Biochem (2011) 0.83
Patterns of sexually transmitted infections in adolescents and youth in Dar es Salaam, Tanzania. BMC Infect Dis (2006) 0.81
Chlamydia trachomatis infection induces replication of latent HHV-6. PLoS One (2013) 0.80
Prevalence and associated factors for four sexually transmissible microorganisms in middle-aged men receiving general prostate health checkups: a polymerase chain reaction-based study in Korea. Korean J Urol (2013) 0.78
Rapid screening for Chlamydia trachomatis infection by detecting α-mannosidase activity in urogenital tract specimens. BMC Infect Dis (2013) 0.77
Molecular Diagnosis of Sexually Transmitted Chlamydia trachomatis in the United States. ISRN Obstet Gynecol (2011) 0.75
Should we consider alternatives to combined cervical and urethral swabs for detection of Chlamydia trachomatis in females? Sex Transm Infect (2007) 0.75
Disseminated gonococcal infections caused by Neisseria gonorrhoeae with unique nutritional requirements. J Infect Dis (1975) 7.92
Ligase chain reaction to detect Chlamydia trachomatis infection of the cervix. J Clin Microbiol (1994) 5.15
Multicenter evaluation of the BDProbeTec ET System for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine specimens, female endocervical swabs, and male urethral swabs. J Clin Microbiol (2001) 4.92
Diagnosis of urogenital Chlamydia trachomatis infection in women based on mailed samples obtained at home: multipractice comparative study. BMJ (1996) 4.82
Strand displacement amplification--an isothermal, in vitro DNA amplification technique. Nucleic Acids Res (1992) 4.47
Current methods of laboratory diagnosis of Chlamydia trachomatis infections. Clin Microbiol Rev (1997) 4.37
Home screening for chlamydial genital infection: is it acceptable to young men and women? Sex Transm Infect (2000) 3.46
Diagnosis by AMPLICOR PCR of Chlamydia trachomatis infection in urine samples from women and men attending sexually transmitted disease clinics. J Clin Microbiol (1996) 2.88
Comparison of three commercially available amplification assays, AMP CT, LCx, and COBAS AMPLICOR, for detection of Chlamydia trachomatis in first-void urine. J Clin Microbiol (1997) 2.71
Diagnosis of Neisseria gonorrhoeae infections in women by using the ligase chain reaction on patient-obtained vaginal swabs. J Clin Microbiol (1997) 2.54
Vulval swabs as alternative specimens for ligase chain reaction detection of genital chlamydial infection in women. J Clin Microbiol (1997) 2.49
The vaginal introitus: a novel site for Chlamydia trachomatis testing in women. Am J Obstet Gynecol (1996) 2.41
Detection of Neisseria gonorrhoeae and Chlamydia trachomatis in genitourinary specimens from men and women by a coamplification PCR assay. J Clin Microbiol (1997) 2.22
Strand displacement amplification and homogeneous real-time detection incorporated in a second-generation DNA probe system, BDProbeTecET. Clin Chem (1999) 2.01
Comparison between the LCx Probe system and the COBAS AMPLICOR system for detection of Chlamydia trachomatis and Neisseria gonorrhoeae infections in patients attending a clinic for treatment of sexually transmitted diseases in Amsterdam, The Netherlands. J Clin Microbiol (2001) 1.95
Evaluation of the abbott LCx assay for detection of Neisseria gonorrhoeae in endocervical swab specimens from females. J Clin Microbiol (1998) 1.53
Recent advances in diagnosis of sexually transmitted diseases. Sex Transm Dis (1994) 1.39
Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med (2015) 9.20
Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study. Lancet HIV (2015) 4.33
Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol (2002) 4.18
Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin Infect Dis (2003) 3.24
Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. Clin Infect Dis (2003) 3.20
Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS (2011) 2.86
Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol (2006) 2.56
Absence of ageism in access to critical care: a cross-sectional study. Age Ageing (2003) 2.14
A delicate balance: risk factors for acquisition of bacterial vaginosis include sexual activity, absence of hydrogen peroxide-producing lactobacilli, black race, and positive herpes simplex virus type 2 serology. Sex Transm Dis (2008) 2.09
Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. J Infect Dis (2002) 2.09
Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-1-infected and high-risk HIV-1-uninfected women. J Infect Dis (2005) 2.04
A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am J Epidemiol (2005) 1.94
Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol (2002) 1.85
Douching in relation to bacterial vaginosis, lactobacilli, and facultative bacteria in the vagina. Obstet Gynecol (2002) 1.73
Colonization of the rectum by Lactobacillus species and decreased risk of bacterial vaginosis. J Infect Dis (2005) 1.72
Home screening for sexually transmitted diseases in high-risk young women: randomised controlled trial. Sex Transm Infect (2007) 1.70
Prevention of sexually transmitted diseases (STDs) in female sex workers: prospective evaluation of condom promotion and strengthened STD services. Sex Transm Dis (2003) 1.70
Vaginal yeast colonization in nonpregnant women: a longitudinal study. Obstet Gynecol (2004) 1.65
Bacterial vaginosis and anaerobic bacteria are associated with endometritis. Clin Infect Dis (2004) 1.65
Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol (2007) 1.63
Genital tract shedding of herpes simplex virus type 2 in women: effects of hormonal contraception, bacterial vaginosis, and vaginal group B Streptococcus colonization. Clin Infect Dis (2005) 1.60
Bacterial vaginosis: identifying research gaps proceedings of a workshop sponsored by DHHS/NIH/NIAID. Sex Transm Dis (2010) 1.59
Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc Natl Acad Sci U S A (2003) 1.56
Rectal applications of nonoxynol-9 cause tissue disruption in a monkey model. Sex Transm Dis (2002) 1.54
Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study. Contraception (2006) 1.52
Risk factors for infection with herpes simplex virus type 2: role of smoking, douching, uncircumcised males, and vaginal flora. Sex Transm Dis (2003) 1.44
Glycosidase and proteinase activity of anaerobic gram-negative bacteria isolated from women with bacterial vaginosis. Sex Transm Dis (2003) 1.38
The associations between pelvic inflammatory disease, Trichomonas vaginalis infection, and positive herpes simplex virus type 2 serology. Sex Transm Dis (2006) 1.35
Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators. PLoS One (2011) 1.28
Why women douche and why they may or may not stop. Sex Transm Dis (2003) 1.26
Antimicrobial resistance associated with the treatment of bacterial vaginosis. Am J Obstet Gynecol (2004) 1.24
The occurrence of vaginal infections among HIV-infected and high-risk HIV-uninfected women: longitudinal findings of the women's interagency HIV study. J Acquir Immune Defic Syndr (2006) 1.24
Association of sexual activity with colonization and vaginal acquisition of group B Streptococcus in nonpregnant women. Am J Epidemiol (2002) 1.24
Limitations of the dye-based method for determining vaginal applicator use in microbicide trials. Sex Transm Dis (2009) 1.24
Predictive value of the clinical diagnosis of lower genital tract infection in women. Am J Obstet Gynecol (2004) 1.21
Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol (2004) 1.20
Why nonoxynol-9 may have failed to prevent acquisition of Neisseria gonorrhoeae in clinical trials. Sex Transm Dis (2005) 1.19
Factors associated with absence of H2O2-producing Lactobacillus among women with bacterial vaginosis. J Infect Dis (2005) 1.16
Comparative genomic analyses of 17 clinical isolates of Gardnerella vaginalis provide evidence of multiple genetically isolated clades consistent with subspeciation into genovars. J Bacteriol (2012) 1.13
Cytokines, pregnancy, and bacterial vaginosis: comparison of levels of cervical cytokines in pregnant and nonpregnant women with bacterial vaginosis. J Infect Dis (2007) 1.12
DNA fingerprinting of Lactobacillus crispatus strain CTV-05 by repetitive element sequence-based PCR analysis in a pilot study of vaginal colonization. J Clin Microbiol (2003) 1.11
Clinical and cervical cytokine response to treatment with oral or vaginal metronidazole for bacterial vaginosis during pregnancy: a randomized trial. Obstet Gynecol (2003) 1.10
Endometritis does not predict reproductive morbidity after pelvic inflammatory disease. Am J Obstet Gynecol (2003) 1.09
Douching, pelvic inflammatory disease, and incident gonococcal and chlamydial genital infection in a cohort of high-risk women. Am J Epidemiol (2005) 1.09
Improved methods for typing nontypeable isolates of group B streptococci. Int J Med Microbiol (2002) 1.09
Vaginal colonization by probiotic Lactobacillus crispatus CTV-05 is decreased by sexual activity and endogenous Lactobacilli. J Infect Dis (2009) 1.08
Decreased cervical proinflammatory cytokines permit subsequent upper genital tract infection during pregnancy. Am J Obstet Gynecol (2003) 1.08
Development of a nonhuman primate model for Trichomonas vaginalis infection. Sex Transm Dis (2006) 1.08
Vaginal and rectal topical microbicide development: safety and efficacy of 1.0% Savvy (C31G) in the pigtailed macaque. Sex Transm Dis (2006) 1.07
Quantitative survival of aerobic and anaerobic microorganisms in Port-A-Cul and Copan transport systems. J Clin Microbiol (2008) 1.07
Is bacterial vaginosis a stronger risk factor for preterm birth when it is diagnosed earlier in gestation? Am J Obstet Gynecol (2005) 1.06
Interlaboratory reproducibility of female genital tract cytokine measurements by Luminex: implications for microbicide safety studies. Cytokine (2011) 1.05
Use of nucleic acid amplification testing for diagnosis of anorectal sexually transmitted infections. J Clin Microbiol (2012) 1.03
Distribution of genital Lactobacillus strains shared by female sex partners. J Infect Dis (2009) 1.03
DNA macrorestriction analysis of nontypeable group B streptococcal isolates: clonal evolution of nontypeable and type V isolates. J Clin Microbiol (2005) 1.03
Comparison of API 50 CH strips to whole-chromosomal DNA probes for identification of Lactobacillus species. J Clin Microbiol (2005) 1.02
Racial disparity in risk of preterm birth associated with lower genital tract infection. Paediatr Perinat Epidemiol (2007) 1.01
Subclinical pelvic inflammatory disease and infertility. Obstet Gynecol (2012) 1.01
Association between elevated neutrophil defensin levels and endometritis. J Infect Dis (2002) 1.01
The vaginal inflammatory milieu and the risk of early premature preterm rupture of membranes. Am J Obstet Gynecol (2005) 1.00
Permeability of tritiated water through human cervical and vaginal tissue. J Pharm Sci (2004) 1.00
Laboratory testing policies and their effects on routine surveillance of community antimicrobial resistance. J Antimicrob Chemother (2004) 0.99
HIV-1 infection of female genital tract tissue for use in prevention studies. J Acquir Immune Defic Syndr (2013) 0.99
Host immune consequences of asymptomatic Trichomonas vaginalis infection in pregnancy. Am J Obstet Gynecol (2007) 0.99
Risk factors for cervicitis among women with bacterial vaginosis. J Infect Dis (2006) 0.98
Early pregnancy threshold vaginal pH and Gram stain scores predictive of subsequent preterm birth in asymptomatic women. Am J Obstet Gynecol (2003) 0.97
Elevated vaginal pH and neutrophils are associated strongly with early spontaneous preterm birth. Am J Obstet Gynecol (2003) 0.97
Vaginal polymorphonuclear leukocytes and bacterial vaginosis as markers for histologic endometritis among women without symptoms of pelvic inflammatory disease. Am J Obstet Gynecol (2003) 0.97
Macaca fascicularis vs. Macaca nemestrina as a model for topical microbicide safety studies. J Med Primatol (2004) 0.97
A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film. J Acquir Immune Defic Syndr (2016) 0.95
Effects of physiological fluids on physical-chemical characteristics and activity of topical vaginal microbicide products. J Pharm Sci (2008) 0.95
Clonal analysis of colonizing group B Streptococcus, serotype IV, an emerging pathogen in the United States. J Clin Microbiol (2010) 0.94
Comparison of acute and subclinical pelvic inflammatory disease. Sex Transm Dis (2005) 0.93
Longitudinal reliability of focus glycoprotein G-based type-specific enzyme immunoassays for detection of herpes simplex virus types 1 and 2 in women. J Clin Microbiol (2003) 0.93
Characterization of cyclodextrin inclusion complexes of the anti-HIV non-nucleoside reverse transcriptase inhibitor UC781. AAPS J (2008) 0.93
Premature rupture of the fetal membranes: is the amnion the major determinant? Am J Obstet Gynecol (2006) 0.92
Mucosal Escherichia coli bactericidal activity and immune mediators are associated with HIV-1 seroconversion in women participating in the HPTN 035 trial. J Infect Dis (2012) 0.92
Maternal antibody at delivery protects neonates from early onset group B streptococcal disease. J Infect Dis (2013) 0.92
Plasma versus serum for detection of herpes simplex virus type 2-specific immunoglobulin G antibodies with a glycoprotein G2-based enzyme immunoassay. J Clin Microbiol (2003) 0.92
Toward early safety alert endpoints: exploring biomarkers suggestive of microbicide failure. AIDS Res Hum Retroviruses (2013) 0.92
Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1. J Acquir Immune Defic Syndr (2014) 0.91
Incidence and epidemiology of Streptococcus pseudoporcinus in the genital tract. J Clin Microbiol (2010) 0.90
Vaginal hydrolytic enzymes, immunoglobulin A against Gardnerella vaginalis toxin, and risk of early preterm birth among women in preterm labor with bacterial vaginosis or intermediate flora. Am J Obstet Gynecol (2002) 0.90
Lactobacillus crispatus capsules: single-use safety study in the Macaca nemestrina model. Sex Transm Dis (2003) 0.89
Pregnancy-induced changes in immune protection of the genital tract: defining normal. Am J Obstet Gynecol (2013) 0.89
Cervical anti-inflammatory cytokine concentrations among first-trimester pregnant smokers. Am J Obstet Gynecol (2005) 0.88
Rectal colonization by group B Streptococcus as a predictor of vaginal colonization. Am J Obstet Gynecol (2009) 0.88
Women's satisfaction with an intravaginal Lactobacillus capsule for the treatment of bacterial vaginosis. J Womens Health (Larchmt) (2006) 0.87
Adherence of Lactobacillus crispatus to vaginal epithelial cells from women with or without a history of recurrent urinary tract infection. J Urol (2006) 0.87
A little bit pregnant: modeling how the accurate detection of pregnancy can improve HIV prevention trials. Am J Epidemiol (2008) 0.87
Microflora changes with the use of a vaginal microbicide. Sex Transm Dis (2002) 0.86
Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines. Vaccine (2012) 0.86
Formulation and characterization of polymeric films containing combinations of antiretrovirals (ARVs) for HIV prevention. Pharm Res (2014) 0.86
The complexity of contraceptives: understanding their impact on genital immune cells and vaginal microbiota. AIDS (2013) 0.85